alexa Protease Inhibitors for Recurrent Hepatitis C after Liv
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Protease Inhibitors for Recurrent Hepatitis C after Liver Transplantation-When Less is More

Sandeep Mukherjee*

Section of Gastroenterology and Hepatology, Nebraska Medical Center, USA

*Corresponding Author:
Dr. Sandeep Mukherjee
Section of Gastroenterology and Hepatology
Nebraska Medical Center
Omaha, NE 68198-3285, USA
E-mail: [email protected]

Received Date: December 22, 2011; Accepted Date: December 24, 2011; Published Date: December 26, 2011

Citation: Mukherjee S (2012) Protease Inhibitors for Recurrent Hepatitis C after Liver Transplantation-When Less is More. J Antivir Antiretrovir 4: i-i. doi: 10.4172/jaa.1000e101

Copyright: © 2012 Mukherjee S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



The approval of boceprevir and telaprevir, two protease inhibitors for hepatitis C (HCV) treatment earlier this year, was met with virtually universal optimism as the addition of these medications will lead to a significantly improved chance of viral eradication in HCV genotype 1 patients. However, this enthusiasm is yet to be embraced by the liver transplant community primarily due to the interaction between protease inhibitors and calcineurin inhibitors such as cyclosporine and tacrolimus. Boceprevir and telaprevir inhibit cytochrome P450 3A which metabolizes cyclosporine and tacrolimus leading to elevated and potentially lethal levels of these calcineurin inhibitors.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version